EUVIMEDEUVIMED entdecken
Crossref

Treatment outcomes of extraskeletal Ewing sarcoma

Matthew T Houdek, Mark J Heidenreich, Safia K Ahmed, Wendy Allen-Rhoades, Brittany L Siontis, Steven I Robinson, Ivy A Petersen, Peter S Rose

Journal of Surgical Oncology · 2023-07 · 128 (1) · 105-110

DOI: 10.1002/jso.27250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 31.03.2023. Verfasst von Matthew T Houdek und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Bone Neoplasms, Sarcoma, Sarcoma, Ewing. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Extraskeletal Ewing sarcoma (EES), is a rare soft tissue sarcoma. Treatment for EES commonly involves chemotherapy and surgical resection (ST) or less commonly combined chemotherapy, surgery, and radiotherapy (ST + RT). The purpose of the current study was to evaluate our institutional experience treating EES.

Methods

We reviewed 36 (18 males:18 females) patients (mean age 30 years) with a nonretroperitoneal/visceral EES treated with either ST ( n = 24, 67%) or ST + RT ( n = 12, 33%). All patients were treated with chemotherapy, most commonly vincristine, doxorubicin, cyclophosphamide/ifosfamide and etoposide (VDC/IE, n = 23, 66%) Radiotherapy was mostly delivered preoperatively ( n = 9). The mean follow‐up was 8 years.

Results

The 10‐year disease specific survival for patients was 78%, with no difference in the survival between patients in the ST versus the ST + RT groups (83% vs. 71%, p = 0.86). There was no difference in the 10‐year local recurrence (91% vs. 100%, p = 0.29) or metastatic free survival (87% vs. 75%, p = 0.45) between the ST and ST + RT groups.

Conclusion

The results of the current study highlight the ability to achieve excellent local control with chemotherapy and surgery for EES. We recommend for multidisciplinary management of patients with EES, including chemotherapy and surgery, with use of radiotherapy if there is concern for a potentially close margin of resection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsSarcomaSarcoma, EwingAdultFemaleHumansMaleAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinEtoposideTreatment OutcomeVincristine

Stichwörter der Autor:innen

Ewing sarcomaextraosseousoutcomesoft-tissue sarcoma

Substanzen

CyclophosphamideDoxorubicinEtoposideVincristine

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona, USA.
  • Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Medical Oncology, Mayo Clinic , Rochester, Minnesota, USA.
  • Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.

Zitieren

APA

Houdek, M. T., Heidenreich, M. J., Ahmed, S. K., Allen-Rhoades, W., Siontis, B. L., Robinson, S. I., Petersen, I. A., & Rose, P. S. (2023). Treatment outcomes of extraskeletal Ewing sarcoma. Journal of Surgical Oncology, 128(1), 105-110. https://doi.org/10.1002/jso.27250

Vancouver

Houdek MT, Heidenreich MJ, Ahmed SK, Allen-Rhoades W, Siontis BL, Robinson SI, et al. Treatment outcomes of extraskeletal Ewing sarcoma. Journal of Surgical Oncology. 2023;128(1):105-110. doi:10.1002/jso.27250

BibTeX
@article{Houdek2023,
  author = {Houdek, Matthew T and Heidenreich, Mark J and Ahmed, Safia K and Allen-Rhoades, Wendy and Siontis, Brittany L and Robinson, Steven I and Petersen, Ivy A and Rose, Peter S},
  title = {Treatment outcomes of extraskeletal Ewing sarcoma},
  journal = {Journal of Surgical Oncology},
  year = {2023},
  volume = {128},
  number = {1},
  pages = {105--110},
  doi = {10.1002/jso.27250}
}
Kostenlos starten →